CStone Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · China · 201-500 Employees
View Company Info for Free
Overview
Headquarters
C1 Building 218 Xinghu Street North Bloc...Phone Number
+86 51287186550Website
www.cstonepharma.comRevenue
$63.7 MillionIndustry
About CStone Pharmaceuticals
CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received eight drug approvals for four drugs. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.Explore more
CStone Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
CStone Pharmaceuticals Tech Stack
A closer look at the technologies used by CStone Pharmaceuticals
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding CStone Pharmaceuticals
Sign Up For FreeTo access detailed company insights
CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience... Read More
